PMID- 22426810
OWN - NLM
STAT- MEDLINE
DCOM- 20130425
LR  - 20211021
IS  - 1532-2807 (Electronic)
IS  - 1219-4956 (Linking)
VI  - 18
IP  - 4
DP  - 2012 Oct
TI  - Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early 
      breast cancer.
PG  - 885-94
AB  - The aim of this study was to analyze the occurrence of TOP2A gene amplification 
      and chromosome 17 polysomy in patients with early breast cancer and to correlate 
      the status of these alterations with the prognostic significance expressed as 
      patients' clinical features and survival. Such concurrent analyses of TOP2A gene 
      status and chromosome 17 polysomy have not been performed before. Study group 
      included 149 consecutive stage I-III patients administered standard multimodality 
      treatment. TOP2A abnormalities were examined by standard fluorescence in situ 
      hybridization (FISH) and developed by our group quantitative real-time PCR 
      (qPCR). TOP2A amplification and deletion assessed by FISH were found in 23% and 
      7% of the tumours, respectively, and by qPCR in 31% and 11% of the tumours, 
      respectively. Chromosome 17 polysomy was detected in 40% of the cases. TOP2A 
      amplification (by qPCR) correlated with shorter disease-free survival (p = 0.03) 
      and overall survival (p = 0.047), and the prognostic value of TOP2A was confirmed 
      in the multivariate analysis (HR = 3.22, 95% CI 1.09-9.56, p = 0.03). TOP2A gene 
      amplification, but not chromosome 17 polysomy, carries negative prognostic 
      information in early breast cancer. Given the aforementioned results, qPCR might 
      serve as a prognostic tool in determining the patient's prognosis.
FAU - Zaczek, Anna
AU  - Zaczek A
AD  - Laboratory of Cell Biology, Department of Medical Biotechnology, Intercollegiate 
      Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, 
      Debinki 1, 80-211, Gdansk, Poland. azaczek@gumed.edu.pl
FAU - Markiewicz, Aleksandra
AU  - Markiewicz A
FAU - Supernat, Anna
AU  - Supernat A
FAU - Bednarz-Knoll, Natalia
AU  - Bednarz-Knoll N
FAU - Brandt, Burkhardt
AU  - Brandt B
FAU - Seroczynska, Barbara
AU  - Seroczynska B
FAU - Skokowski, Jaroslaw
AU  - Skokowski J
FAU - Szade, Jolanta
AU  - Szade J
FAU - Czapiewski, Piotr
AU  - Czapiewski P
FAU - Biernat, Wojciech
AU  - Biernat W
FAU - Welnicka-Jaskiewicz, Marzena
AU  - Welnicka-Jaskiewicz M
FAU - Jassem, Jacek
AU  - Jassem J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120318
PL  - Switzerland
TA  - Pathol Oncol Res
JT  - Pathology oncology research : POR
JID - 9706087
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Poly-ADP-Ribose Binding Proteins)
RN  - EC 5.99.1.3 (DNA Topoisomerases, Type II)
RN  - EC 5.99.1.3 (TOP2A protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Analysis of Variance
MH  - Aneuploidy
MH  - Antigens, Neoplasm/*genetics
MH  - Breast Neoplasms/diagnosis/*genetics
MH  - *Chromosome Aberrations
MH  - *Chromosomes, Human, Pair 17
MH  - DNA Topoisomerases, Type II/*genetics
MH  - DNA-Binding Proteins/*genetics
MH  - Female
MH  - *Gene Amplification
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Middle Aged
MH  - Poly-ADP-Ribose Binding Proteins
MH  - Prognosis
MH  - Real-Time Polymerase Chain Reaction
EDAT- 2012/03/20 06:00
MHDA- 2013/04/26 06:00
CRDT- 2012/03/20 06:00
PHST- 2011/10/04 00:00 [received]
PHST- 2012/03/07 00:00 [accepted]
PHST- 2012/03/20 06:00 [entrez]
PHST- 2012/03/20 06:00 [pubmed]
PHST- 2013/04/26 06:00 [medline]
AID - 10.1007/s12253-012-9518-8 [doi]
PST - ppublish
SO  - Pathol Oncol Res. 2012 Oct;18(4):885-94. doi: 10.1007/s12253-012-9518-8. Epub 
      2012 Mar 18.